|
Aug 14
|
Leap Therapeutics Reports Second Quarter 2025 Financial Results
|
|
Jun 23
|
Leap Therapeutics' Colorectal Cancer Study Shows Significant Benefits; Workforce Cuts Coming
|
|
Jun 23
|
Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives
|
|
Aug 12
|
Leap Therapeutics Reports Second Quarter 2024 Financial Results
|
|
May 13
|
Leap Therapeutics Inc (LPTX) Q1 2024 Earnings: Financial Resilience Amidst Clinical Progress
|
|
May 13
|
Leap Therapeutics Reports First Quarter 2024 Financial Results
|
|
Apr 29
|
Pipeline Moves: Investigator-led trial of Lilly’s merestinib in solid tumours terminated
|
|
Apr 11
|
Leap Therapeutics Announces $40 Million Private Placement
|
|
Mar 20
|
Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks
|
|
Mar 18
|
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Jan 2
|
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients
|
|
Apr 26
|
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting
|